

In the Specification:

Replace the text at page 1, line 1, with the following:

A METHOD OF USING IL-11 FOR TREATING MUCOSITIS

Replace the text at page 1, line 3 to line 5, with the following:

*a1*  
This is a Continuation of U.S. Application No. 09/179,026, filed October 26, 1998, now Patent No. 6,126,933, issued October 3, 2000, ~~which is a continuation in part of U.S. Application No. 08/892,407, filed July 15, 1997, now Patent No. 5,948,402, issued September 7, 1999, which is a divisional of U.S. application No. 08/495,724, filed June 27, 1997, now Patent No. 5,679,339, issued October 21, 1997,~~ the entire teachings of which are incorporated herein by reference in their entireties.

Replace the text at page 9, lines 16-28 with the following:

*a2*  
Interleukin (IL-11) is a pleiotropic cytokine that stimulates primitive lymphohematopoietic progenitor cells and synergizes with other hematopoietic growth factors to stimulate the proliferation and maturation of megakaryocytes. IL-11 is described in detail in International Application PCT/US90/06803, published May 30, 1991, as well as in U.S. Patent No. 5,215,895; issued June 1, 1992. A cloned human IL-11 was previously deposited with the ATCC, ~~12301 Parklawn Drive, Rockville, Maryland~~ 10801 University Boulevard, Manassas, VA 20110-2209, on March 30, 1990 under ATCC No. 68284. Moreover, as described in U.S. Patent No. 5,270,181, issued December 14, 1993, and U.S. Patent No. 5,292,646, issued March 8, 1994, IL-11 may also be produced recombinantly as a fusion protein with another protein. IL-11 can be

produced in a variety of host cells by resort to now conventional genetic engineering techniques. In addition, IL-11 can be obtained from various cell lines, for example, the human fibroblast cell line, MRC-5 (ATCC Accession No. CCL 171), and Paul *et al.*, the human trophoblastic cell line, TPA30-1

---